Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 60%Low 2 · 40%Moderate 0 · 0%High 0 · 0%

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.2 [0.83, 1.73]
5 studies · 2994 participants
Low

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major GI bleeding · patients with cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.16 [0.62, 2.17]
4 studies · 1838 participants
Low

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major non‐GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.84 [0.42, 1.68]
4 studies · 1838 participants
Very low

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major upper GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.18 [0.51, 2.76]
4 studies · 1838 participants
Very low

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Major lower GI bleeding · patients with cancer with venous thromboembolism

It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.1 [0.43, 2.8]
4 studies · 1838 participants
Very low